Skip to content
Cerdelga(eliglustat)
Cerdelga (eliglustat) is a small molecule pharmaceutical. Eliglustat was first approved as Cerdelga on 2014-08-19. It is used to treat gaucher disease in the USA. It has been approved in Europe to treat gaucher disease.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Cerdelga (generic drugs available since 2021-09-08)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eliglustat tartrate
Tradename
Company
Number
Date
Products
CERDELGASanofiN-205494 RX2014-08-19
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cerdelgaNew Drug Application2019-12-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
gaucher diseaseOrphanet_355D005776E75.22
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Eliglustat Tartrate, Cerdelga, Genzyme Corp
108885442038-12-13U-3040, U-3041
108885472031-01-31U-3042, U-3043
114581192030-11-24DS, DP
71962052026-06-26DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AX: Various alimentary tract and metabolism products
— A16AX10: Eliglustat
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gaucher diseaseD005776Orphanet_355E75.22315—110
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Hematologic neoplasmsD0193371————1
NeoplasmsD009369C801————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameELIGLUSTAT
INNeliglustat
Description
Eliglustat is a carboxamide obtained by formal condensation of the carboxy group of octanoic acid with the primary amino group of (1R,2R)-2-amino-1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(pyrrolidin-1-yl)propan-1-ol. A ceramide glucosyltransferase inhibitor used (as its tartrate salt) for treatment of Gaucher's disease. It has a role as an EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor. It is a benzodioxine, a N-alkylpyrrolidine, a secondary alcohol and a carboxamide. It is a conjugate base of an eliglustat(1+).
Classification
Small molecule
Drug classenzyme inhibitors: glucosyltransferase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2
Identifiers
PDB—
CAS-ID491833-29-5
RxCUI1547220
ChEMBL IDCHEMBL2110588
ChEBI ID82752
PubChem CID23652731
DrugBankDB09039
UNII IDDR40J4WA67 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 509 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,483 adverse events reported
View more details